schizophrenia

The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Sumitomo, Otsuka’s Schizophrenia Candidate Fails Phase III Trials
BioSpace
Mon, 07/31/23 - 09:50 pm
Sumitomo Pharma
Otsuka
clinical trials
ulotaront
schizophrenia
Roche Terminates Second Phase II Schizophrenia Trial
BioSpace
Tue, 05/23/23 - 11:24 am
Roche
schizophrenia
ralmitaront
clinical trials
J&J beats back Viatris' generic challenge to schizophrenia med Invega Trinza
Fierce Pharma
Thu, 05/18/23 - 11:16 am
JNJ
schizophrenia
generics
Trinza
Viatris
Teva, MedinCell win FDA approval for slow-release schizophrenia drug Uzedy
Fierce Pharma
Mon, 05/1/23 - 10:11 pm
Teva Pharmaceutical
MedinCell
FDA
schizophrenia
Uzedy
Risperidone
Schizophrenia: Four major clinical trials to watch in 2023
Clinical Trials Arena
Thu, 04/13/23 - 10:08 pm
clinical trials
schizophrenia
Reviva
brilaroxazine
Newron
evenamide
Sunovion
ulotaront
Acadia Pharma
pimavanserin
Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful
Endpoints
Thu, 03/23/23 - 11:49 am
Royalty Pharma
Karuna Therapeutics
KarXT
schizophrenia
PureTech
Karuna’s schizophrenia drug succeeds in a second late-stage trial
BioPharma Dive
Mon, 03/20/23 - 09:53 am
Karuna
clinical trials
schizophrenia
KarXT
Newron’s Schizophrenia Candidate Gets Better Over Time
BioSpace
Fri, 02/17/23 - 09:38 am
Newron Pharma
schizophrenia
evenamide
Following in Lilly's footsteps, Teva takes 2nd long-acting schizophrenia drug into phase 3
Fierce Pharma
Tue, 01/31/23 - 12:31 pm
Teva Pharmaceutical
clinical trials
schizophrenia
Eli Lilly
antipsychotics
Olanzapine
TV-44749
Luye claims its first FDA approval, for bi-weekly schizophrenia drug
Pharmaphorum
Tue, 01/17/23 - 11:04 pm
Luye Pharma
China
FDA
schizophrenia
Rykindo
JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate
Fierce Biotech
Tue, 01/10/23 - 06:37 pm
JPMHC 2023
Karuna Therapeutics
drug launches
schizophrenia
KarXT
Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch
Fierce Biotech
Mon, 01/9/23 - 10:31 am
Karuna Therapeutics
schizophrenia
KarXT
drug launches
Newron says pivotal treatment-resistant schizophrenia trial is a go
Pharmaphorum
Tue, 01/3/23 - 10:08 am
Newron Pharma
schizophrenia
evenamide
clinical trials
Boehringer Ingelheim deepens its collaboration with Click Therapeutics in a deal worth $460M
Endpoints
Mon, 12/19/22 - 10:07 pm
Boehringer Ingelheim
Click Therapeutics
digital therapeutics
schizophrenia
Karuna switches CEOs ahead of FDA filing for schizophrenia drug
BioPharma Dive
Tue, 12/6/22 - 08:45 pm
Karuna Therapeutics
Pharma CEOs
schizophrenia
FDA
KarXT
Take 2: Teva refiles for approval of long-acting schizophrenia drug months after FDA rejection
Fierce Pharma
Tue, 11/8/22 - 11:06 am
Teva Pharmaceutical
schizophrenia
FDA
mdc-IRM
Neurocrine randomizes first patient in Phase II schizophrenia therapy trial
Clinical Trials Arena
Fri, 10/28/22 - 10:28 am
Neurocrine Biosciences
clinical trials
NBI-1117568
schizophrenia
Minerva Shares Plunge After FDA Rejects Schizophrenia Drug Candidate
BioSpace
Tue, 10/18/22 - 11:00 am
Minerva Neurosciences
schizophrenia
FDA
roluperidone
Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t
Endpoints
Wed, 10/12/22 - 10:55 am
Merck
Royalty Pharma
schizophrenia
MK-8189

Pages